Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOTRICITY INC.BTCY · Entity 8507 | Director | May 04, 2022 | May 16, 2022 |
| Healthcare Triangle, Inc.HCTI · Entity 7909 | Director | March 12, 2024 | March 13, 2024 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Chief Financial Officer | April 17, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOTRICITY INC.
Report date May 04, 2022 · Filed May 16, 2022
This filing explicitly reported no securities owned.
Healthcare Triangle, Inc.
Report date March 12, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2029-03-12 | Direct | 10,000 |
Reported balance
After 2024-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-12 · Grant · Acquired 5,000 · Balance 10,000 F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 5,000 options vesting immediately. F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.
F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 5,000 options vesting immediately.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date April 17, 2025 · Filed April 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2035-04-16 | Direct | 250,000 |
Reported balance
After 2025-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-17 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2025 Filed Apr 21, 2025 20:44 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 250,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001837830-25-000002 · primary_doc.xml · derivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: 25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:47 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 200,000 | $0.50 | $100,000.00 |
DisclosureSEC source: 0001837830-25-000001 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,117 Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 17:00 UTC | Healthcare Triangle, Inc. HCTI · Entity 7909 | GrantIncentive Stock Option (Right To Buy) · Derivative | 5,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-24-022218 · ownership.xml · derivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2029-03-12 F2 · derivative.underlying_shares: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 5,000 options vesting immediately. F1 · balance_after: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 15:57 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 113,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001837830-24-000001 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,117 F1 · shares: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:53 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 89,283 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001837830-23-000003 · primary_doc.xml · derivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,283 Underlying: Common Stock · 89,283 shares Expires 2033-11-08 F1 · derivative.exercise_date: 25% will vest on November 9, 2024, and the remaining 75% will vest in 36 equal monthly installments on the last day of each month following November 9, 2024. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 15:36 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 50,900 | $0.98 | $50,024.52 |
DisclosureSEC source: 0001837830-23-000002 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,400 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $0.9525 to $0.9893 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 19:39 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 12,500 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001837830-23-000001 · primary_doc.xml · derivative · entry 2 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-04-20 F2 · derivative.exercise_date: 25% will vest on April 21, 2024 and the remaining 75% will vest in 12 equal quarterly installments on the last day of each quarter beginning on June 30, 2024. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 19:39 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001837830-23-000001 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments on the last day of each quarter over the next 8 quarters, subject to continued service on such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 13:54 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 10,000 | $1.02 | $10,219.00 |
DisclosureSEC source: 0001837830-22-000004 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $0.9278 to $1.0599 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:16 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 14,000 | $1.06 | $14,781.20 |
DisclosureSEC source: 0001837830-22-000003 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $1.02 to $1.0888 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 24, 2022 Filed May 24, 2022 20:03 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 10,500 | $0.98 | $10,291.05 |
DisclosureSEC source: 0001837830-22-000002 · primary_doc.xml · nonDerivative · entry 2 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 F2 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $0.9174 to $1.00 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:03 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 17,500 | $0.85 | $14,924.00 |
DisclosureSEC source: 0001837830-22-000002 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $0.80 to $0.878 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 23:37 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001837830-22-000001 · primary_doc.xml · nonDerivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments on the last day of each month over the next 24 months, subject to continued service on such vesting date. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:10 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 140,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001596771-21-000007 · primary_doc.xml · derivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: 25% will vest on January 27, 2022 and remaining 75% will vest in 36 equal monthly installments on the last day of each month beginning on February 28, 2022. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 19:41 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 180,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001213900-21-000388 · ownership.xml · derivative · entry 1 McClurg Ronald W. · CIK 0001837830 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: 25% will vest on January 1, 2022 and the remaining 75% will vest in 36 equal monthly installments beginning on February 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.